2-(4-bromopyridin-2-yl)-1-(4-fluorophenyl)ethanone | 1278250-13-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(4-bromopyridin-2-yl)-1-(4-fluorophenyl)ethanone
• CAS: 1278250-13-7
• 化学式: C₁₃H₉BrFNO
• 分子量: 294.123
• InChiKey: CNWGTEGGSUKLRZ-UHFFFAOYSA-N

物化性质

• 沸点：
  398.2±32.0 °C(Predicted)
• 密度：
  1.506±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  30
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(4-bromopyridin-2-yl)-1-(4-fluorophenyl)ethanone 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 吡啶 、 盐酸羟胺 、 caesium carbonate 、 O-mesitylenesulfonylhydroxylamine 作用下， 以 四氢呋喃 、 乙醇 、 水 、 1,2-二氯乙烷 为溶剂， 反应 7.5h， 生成 1-{3-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-5-yl]phenyl}prop-2-yn-1-ol
  参考文献：
  名称：

  ACETYLENE DERIVATIVES OF 5-PHENYL-PYRAZOLOPYRIDINE, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF

  摘要：

  式(I)的化合物： 其中： R1和R2分别独立地代表氢原子或(C1-C6)烷基基团， R3代表一个或多个氢或卤原子， X代表1至4个取代基，相同或不同，选择自氢、卤素或(C1-C6)烷基， 以碱或与酸形成的加合盐的形式。 治疗用途和合成过程。

  公开号：

  US20120270897A1
• 作为产物：
  描述：

  4-溴-2-甲基吡啶 、 对氟苯甲酸乙酯 在 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 为溶剂， 以88%的产率得到2-(4-bromopyridin-2-yl)-1-(4-fluorophenyl)ethanone
  参考文献：
  名称：

  ACETYLENE DERIVATIVES OF 5-PHENYL-PYRAZOLOPYRIDINE, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF

  摘要：

  式(I)的化合物： 其中： R1和R2分别独立地代表氢原子或(C1-C6)烷基基团， R3代表一个或多个氢或卤原子， X代表1至4个取代基，相同或不同，选择自氢、卤素或(C1-C6)烷基， 以碱或与酸形成的加合盐的形式。 治疗用途和合成过程。

  公开号：

  US20120270897A1

文献信息

• 5-PHENYLPYRAZOLOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF
  申请人：Auger Florian

  公开号：US20130023554A1

  公开（公告）日：2013-01-24

  Compounds of formula (I): in which: R1 represents a phenyl group or naphthyl group, optionally substituted by one or more atoms or groups chosen, independently of one another, from: halogen, (C 1 -C 6 )alkyl, halo(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, halo(C 1 -C 6 )alkoxy, (C 1 -C 6 )thioalkyl, —S(O)(C 1 -C 6 )alkyl, —S(O) 2 (C 1 -C 6 )alkyl, hydroxyl, hydroxy(C 1 -C 6 )alkylene, CHO, COOH, (C 1 -C 6 )alkoxy(C 1 -C 6 )alkyleneoxy, NRaRb, CONRaRb, SO 2 NRaRb, NRcCORd, OC(O)NRaRb, OCO(C 1 -C 6 )alkyl, NRcC(O)ORe or NRcSO 2 Re; X represents from 1 to 4 substituents which are identical to or different from one another and which are chosen from hydrogen, halogen, (C 1 -C 6 )alkyl or (C 1 -C 6 )alkoxy, it being possible for the (C 1 -C 6 )alkyl to be optionally substituted by one or more groups chosen from a halogen, (C 1 -C 6 )alkoxy or hydroxyl; R2 and R3 represent, independently of one another, a hydrogen atom, a (C 1 -C 6 )alkyl group optionally substituted by an Rf group, or a CHO or COOH group; X and R3 can together form, with the carbon atoms which carry them, a carbocycle of 5 to 7 carbon atoms; R4 represents a hydrogen atom or a (C 1 -C 6 )alkyl group; Ra and Rb represent, independently of one another, a hydrogen atom or a (C 1 -C 6 )alkyl, aryl(C 1 -C 6 )alkylene or aryl group; or Ra and Rb together form, with the nitrogen atom which carries them, an azetidine, pyrrolidine, piperidine, azepine, morpholine, thiomorpholine, piperazine or homopiperazine group, this group being optionally substituted by a (C 1 -C 6 )alkyl, aryl or aryl(C 1 -C 6 )alkylene group; Rc and Rd represent, independently of one another, a hydrogen atom or a (C 1 -C 6 )alkyl, aryl(C 1 -C 6 )alkylene or aryl group; or Rc and Rd together form a (C 2 -C 5 )alkylene group; Re represents a (C 1 -C 6 )alkyl, aryl(C 1 -C 6 )alkylene or aryl group; or Rc and Re together form a (C 2 -C 5 )alkylene group; Rf represents a hydroxyl, oxo, CHO or COOH group, in the form of the base or of an addition salt with an acid. Therapeutic use and synthetic process.

  公式（I）的化合物：其中：R1代表苯基或萘基，可选择地被一个或多个独立选择的原子或基团取代，这些基团包括：卤素，（C1-C6）烷基，卤代（C1-C6）烷基，（C1-C6）氧烷基，卤代（C1-C6）氧烷基，（C1-C6）硫基烷基，—S（O）（C1-C6）烷基，—S（O）2（C1-C6）烷基，羟基，羟基（C1-C6）烷基烯基，CHO，COOH，（C1-C6）氧烷氧基，NRaRb，CONRaRb，SO2NRaRb，NRcCORd，OC（O）NRaRb，OCO（C1-C6）烷基，NRcC（O）ORe或NRcSO2Re；X代表1到4个取代基，这些取代基可以相同也可以不同，可以选择为氢，卤素，（C1-C6）烷基或（C1-C6）氧烷基，其中（C1-C6）烷基可以选择性地被一个或多个卤素，（C1-C6）氧烷基或羟基取代；R2和R3分别代表氢原子，可选择性地被Rf基团取代的（C1-C6）烷基基团，或CHO或COOH基团；X和R3可以与携带它们的碳原子一起形成5到7个碳原子的碳环；R4代表氢原子或（C1-C6）烷基基团；Ra和Rb分别代表氢原子或（C1-C6）烷基，芳基（C1-C6）烷基或芳基；或Ra和Rb可以与携带它们的氮原子一起形成氮杂环，例如氮杂丙烷，吡咯烷，哌咯烷，氮杂庚烷，吗啉，硫代吗啉，哌嗪或同半哌嗪基团，该基团可选择性地被（C1-C6）烷基，芳基或芳基（C1-C6）烷基基团取代；Rc和Rd分别代表氢原子或（C1-C6）烷基，芳基（C1-C6）烷基或芳基；或Rc和Rd可以一起形成（C2-C5）烷基基团；Re代表（C1-C6）烷基，芳基（C1-C6）烷基或芳基基团；或Rc和Re可以一起形成（C2-C5）烷基基团；Rf代表羟基，氧基，CHO或COOH基团，以碱或酸的加成盐形式存在。治疗用途和合成方法。
• DIPHENYL-PYRAZOLOPYRIDINE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF AS NUCLEAR RECEPTOR NOT MODULATORS
  申请人：Auger Florian

  公开号：US20120245164A1

  公开（公告）日：2012-09-27

  The invention relates to a formula (I), in which R is a hydrogen or halogen atom or a (C1-C6)alkyl group; X is one or more substituents selected from a hydrogen or halogen atom, a (C1-C6)alkyl, halo(C1-C6)alkyl, (C1-C6)alkoxy, halo(C1-C6)alkoxy, cyano, hydroxy, or hydroxy(C1-C6)alkyl group; Y is a hydrogen or halogen atom or a (C1-C6)alkyl group; R1 is an NR2R3 or OR4 group; R2 and R3 independently are a hydrogen atom, a (C1-C6)alkyl, hydroxy(C1-C6)alkyl or oxo(C1-C6)alkyl group or R2 and R3, together with the nitrogen atom supporting the same, form a heterocycle optionally substituted by a (C1-C6)alkyl, hydroxy or oxo group; and R4 is a (C1-C6)alkyl, hydroxy(C1-C6)alkyl, or oxo(C1-C6)alkyl group, in the base or acid addition salt state. Said formula can be used therapeutically for treating or preventing diseases linked to the nuclear receptors Nurr-1, also known as NR4A2, NOT, TINUR, RNR-1, and HZF3.

  该发明涉及一种公式（I），其中R是氢原子或卤素原子或（C1-C6）烷基基团；X是一个或多个取自氢原子或卤素原子，（C1-C6）烷基，卤代（C1-C6）烷基，（C1-C6）氧烷基，卤代（C1-C6）氧烷基，氰基，羟基或羟基（C1-C6）烷基基团的取代基；Y是氢原子或卤素原子或（C1-C6）烷基基团；R1是NR2R3或OR4基团；R2和R3分别是氢原子，（C1-C6）烷基，羟基（C1-C6）烷基或氧代（C1-C6）烷基基团，或者R2和R3与支持它们的氮原子一起形成一个杂环，该杂环可以选择地被（C1-C6）烷基，羟基或氧代基团取代；R4是（C1-C6）烷基，羟基（C1-C6）烷基或氧代（C1-C6）烷基基团，在碱性或酸性加合盐状态下。该公式可以在治疗或预防与核受体Nurr-1（也称为NR4A2，NOT，TINUR，RNR-1和HZF3）相关的疾病方面进行治疗。
• Diphenyl-pyrazolopyridine derivatives, preparation thereof, and use thereof as nuclear receptor not modulators
  申请人：Auger Florian

  公开号：US08680096B2

  公开（公告）日：2014-03-25

  The invention relates to a formula (I), in which R is a hydrogen or halogen atom or a (C1-C6)alkyl group; X is one or more substituents selected from a hydrogen or halogen atom, a (C1-C6)alkyl, halo(C1-C6)alkyl, (C1-C6)alkoxy, halo(C1-C6)alkoxy, cyano, hydroxy, or hydroxy(C1-C6)alkyl group; Y is a hydrogen or halogen atom or a (C1-C6)alkyl group; R1 is an NR2R3 or OR4 group; R2 and R3 independently are a hydrogen atom, a (C1-C6)alkyl, hydroxy(C1-C6)alkyl or oxo(C1-C6)alkyl group or R2 and R3, together with the nitrogen atom supporting the same, form a heterocycle optionally substituted by a (C1-C6)alkyl, hydroxy or oxo group; and R4 is a (C1-C6)alkyl, hydroxy(C1-C6)alkyl, or oxo(C1-C6)alkyl group, in the base or acid addition salt state. Said formula can be used therapeutically for treating or preventing diseases linked to the nuclear receptors Nurr-1, also known as NR4A2, NOT, TINUR, RNR-1, and HZF3.

  本发明涉及一种式(I)，其中R是氢或卤素原子或(C1-C6)烷基；X是氢或卤素原子、(C1-C6)烷基、卤代(C1-C6)烷基、(C1-C6)烷氧基、卤代(C1-C6)烷氧基、氰基、羟基或羟基(C1-C6)烷基中的一种或多种取代基；Y是氢或卤素原子或(C1-C6)烷基；R1是NR2R3或OR4基团；R2和R3独立地是氢原子、(C1-C6)烷基、羟基(C1-C6)烷基或氧代(C1-C6)烷基或者R2和R3与支持它们的氮原子一起形成一个杂环，该杂环可以选择地由(C1-C6)烷基、羟基或氧代基团取代；R4是(C1-C6)烷基、羟基(C1-C6)烷基或氧代(C1-C6)烷基团，在酸盐或碱盐的状态下。该式可用于治疗或预防与核受体Nurr-1有关的疾病，也称为NR4A2、NOT、TINUR、RNR-1和HZF3。
• 5-phenylpyrazolopyridine derivatives, preparation and therapeutic use thereof
  申请人：Auger Florian

  公开号：US08618301B2

  公开（公告）日：2013-12-31

  The present invention relates to compounds of formula (I).

  本发明涉及式(I)的化合物。
• Acetylene derivatives of 5-phenyl-pyrazolopyridine, preparation thereof, and therapeutic use thereof
  申请人：Auger Florian

  公开号：US08546424B2

  公开（公告）日：2013-10-01

  Compounds of formula (I): in which: R1 and R2 represent, independently of one another, a hydrogen atom or a (C1-C6)alkyl group, R3 represents one or more hydrogen or halogen atoms, X represents from 1 to 4 substituents, identical to or different from one another, chosen from hydrogen, halogen or (C1-C6)alkyl, in the form of the base or of an addition salt with an acid. Therapeutic use and synthetic process.

  式（I）的化合物：其中：R1和R2分别独立地表示氢原子或（C1-C6）烷基，R3表示一个或多个氢或卤原子，X表示1到4个取代基，相同或不同，选自氢、卤素或（C1-C6）烷基，以碱或酸加成盐的形式存在。治疗用途和合成过程。